drugset / Trial / NCT04161118
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Timeline
- Start
- 2021-05-12
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | 6e+07 cells | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 6e+08 cells | Intravenous |